DNTH Projected Dividend Yield
Dianthus Therapeutics Inc ( NASDAQ : DNTH )Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. Co. is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. Co. has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. 21 YEAR PERFORMANCE RESULTS |
DNTH Dividend History Detail DNTH Dividend News DNTH Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |